Last reviewed · How we verify

MEDI8897 — Competitive Intelligence Brief

MEDI8897 (MEDI8897) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RSV monoclonal antibody. Area: Immunology / Infectious Disease.

phase 3 RSV monoclonal antibody RSV fusion (F) protein Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

MEDI8897 (MEDI8897) — MedImmune LLC. MEDI8897 is a monoclonal antibody that provides extended half-life neutralization of respiratory syncytial virus (RSV) through engineered Fc region modifications.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MEDI8897 TARGET MEDI8897 MedImmune LLC phase 3 RSV monoclonal antibody RSV fusion (F) protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RSV monoclonal antibody class)

  1. MedImmune LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MEDI8897 — Competitive Intelligence Brief. https://druglandscape.com/ci/medi8897. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: